Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Genta deal

GNTA received an option from Jagotec AG (Hergiswil, Switzerland) to form a second 50/50 joint venture to develop

Read the full 181 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE